Gap junctional remodeling by hypoxia in cultured neonatal rat ventricular myocytes

Department of Pharmacology, Columbia University, New York, New York, United States
Cardiovascular Research (Impact Factor: 5.94). 05/2005; 66(1):64-73. DOI: 10.1016/j.cardiores.2005.01.014
Source: PubMed


Altered gap junctional coupling of ventricular myocytes plays an important role in arrhythmogenesis in ischemic heart disease. Since hypoxia is a major component of ischemia, we tested the hypothesis that hypoxia causes gap junctional remodeling accompanied by conduction disturbances.
Cultured neonatal rat ventricular myocytes were exposed to hypoxia (1% O(2)) for 15 min to 5 h, connexin43 (Cx43) expression was analyzed, and conduction velocity was measured using the Micro-Electrode Array data acquisition system.
After 15 min of hypoxia, conduction velocity was unaffected, while total Cx43, including the phosphorylated and nonphosphorylated isoforms, was increased. After 5 h of hypoxia, total Cx43 protein was decreased by 50%, while the nonphosphorylated Cx43 isoform was unchanged. Confocal analyses yielded a 55% decrease in the gap junctional Cx43 fluorescence signal, a 55% decrease in gap junction number, and a 26% decrease in size. The changes in Cx43 were not accompanied by changes in mRNA levels. The reduction in Cx43 protein levels was associated with a approximately 20% decrease in conduction velocity compared to normoxic cultures.
Short-term hypoxia (5 h) decreases Cx43 protein and conduction velocity, thereby contributing to the generation of an arrhythmogenic substrate.

1 Follower
18 Reads
  • Source
    • "To determine whether the decrease in intercellular coupling and Cx43 protein expression by doxorubicin and the beneficiary effects of TVP1022 are correlated with corresponding alterations in the activation properties and conduction velocity, we measured extracellular electrograms from NRVM cultures by means of the MEA setup (Meiry et al., 2001; Zeevi-Levin et al., 2005). These experiments showed (Fig. 7) that only in the doxorubicin group, conduction velocity (P Ͻ 0.01), QRS amplitude (P Ͻ 0.001), and dV/dt max (P Ͻ 0.01) were significantly decreased at 48 h, compared with the 0-h time point. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Our recent studies demonstrated that propargylamine derivatives such as rasagiline (Azilect, Food and Drug Administration-approved anti-Parkinson drug) and its S-isomer TVP1022 protect cardiac and neuronal cell cultures against apoptotic-inducing stimuli. Studies on structure-activity relationship revealed that their neuroprotective effect is associated with the propargylamine moiety, which protects mitochondrial viability and prevents apoptosis by activating Bcl-2 and protein kinase C-epsilon and by down-regulating the proapoptotic protein Bax. Based on the established cytoprotective and neuroprotective efficacies of propargylamine derivatives, as well as on our recent study showing that TVP1022 attenuates serum starvation-induced and doxorubicin-induced apoptosis in neonatal rat ventricular myocytes (NRVMs), we tested the hypothesis that TVP1022 will also provide protection against doxorubicin-induced NRVM functional derangements. The present study demonstrates that pretreatment of NRVMs with TVP1022 (1 microM, 24 h) prevented doxorubicin (0.5 microM, 24 h)-induced elevation of diastolic [Ca(2+)](i), the slowing of [Ca(2+)](i) relaxation kinetics, and the decrease in the rates of myocyte contraction and relaxation. Furthermore, pretreatment with TVP1022 attenuated the doxorubicin-induced reduction in the protein expression of sarco/endoplasmic reticulum calcium (Ca(2+)) ATPase, Na(+)/Ca(2+) exchanger 1, and total connexin 43. Finally, TVP1022 diminished the inhibitory effect of doxorubicin on gap junctional intercellular coupling (measured by means of Lucifer yellow transfer) and on conduction velocity, the amplitude of the activation phase, and the maximal rate of activation (dv/dt(max)) measured by the Micro-Electrode-Array system. In summary, our results indicate that TVP1022 acts as a novel cardioprotective agent against anthracycline cardiotoxicity, and therefore potentially can be coadmhence, theinistered with doxorubicin in the treatment of malignancies in humans.
    Journal of Pharmacology and Experimental Therapeutics 11/2009; 332(2):413-20. DOI:10.1124/jpet.109.161158 · 3.97 Impact Factor
  • Source
    • "Reduction of intercellular coupling under such circumstances might reduce this effect, however [24]. Direct evidence of changes in ion currents will be needed to clarify the interference of changes in excitability with the investigated relationship between Cx43 content and CV due to hypoxia in the study of Zeevi-Levin [7]. "
    Cardiovascular Research 05/2005; 66(1). DOI:10.1016/j.cardiores.2005.02.003 · 5.94 Impact Factor
  • Source
Show more